CN109125303A - A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein - Google Patents
A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein Download PDFInfo
- Publication number
- CN109125303A CN109125303A CN201811084266.3A CN201811084266A CN109125303A CN 109125303 A CN109125303 A CN 109125303A CN 201811084266 A CN201811084266 A CN 201811084266A CN 109125303 A CN109125303 A CN 109125303A
- Authority
- CN
- China
- Prior art keywords
- rabbit
- hemorrhagic disease
- capsid protein
- disease virus
- rabbit hemorrhagic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract description 26
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 25
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000008569 process Effects 0.000 title claims description 5
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims abstract description 32
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930000755 gossypol Natural products 0.000 claims abstract description 16
- 229950005277 gossypol Drugs 0.000 claims abstract description 16
- 230000015556 catabolic process Effects 0.000 claims abstract description 9
- 238000006731 degradation reaction Methods 0.000 claims abstract description 9
- 241000700605 Viruses Species 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 22
- 230000003612 virological effect Effects 0.000 abstract description 11
- 208000036142 Viral infection Diseases 0.000 abstract description 10
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 208000031169 hemorrhagic disease Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000000593 degrading effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000002845 virion Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- -1 naphthalene aldehyde compounds Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002507 anti-phytoviral effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of methods using gossypol degradation rabbit hemorrhagic disease virus capsid protein.For the upper status for reaching the treatment virosis purpose there has been no degradation rabbit hemorrhagic disease virus capsid protein of production, to influence the stability of virion the treatment of virosis is advantageously implemented using gossypol viral capsid proteins of directly degrading.Compared with the upper traditional rabbit hemorrhagic disease prevention and control of production mainly pass through the progress virosis prevention such as antibiotic, vaccine, this technology is directly degraded rabbit hemorrhagic disease virus capsid protein using gossypol, to be expected to directly treat virosis, the mode of action is novel, safety is also higher, and the sound development of rabbit industry is beneficial to after.
Description
One, technical field
The invention belongs to animal virosis Control Technology fields, and in particular to a kind of to utilize gossypol degradation rabbit hemorrhagic disease virus
The method of capsid protein.
Two, technical background
With the improvement of people ' s living standards and the diversification of dietary structure, the cultivation amount of rabbit are also increasing.With
The increasing of rabbit cultivation amount, the frequency of occurrences of rabbit is also higher and higher, brings significant damage, especially rabbit viral to rabbit keeping
The harm of haemorrhage is the most serious, caused by economic loss it is very big.Rabbit hemorrhagic disease is also known as rabbit hemorrhagic pneumonia, rabbit bleeding
Disease or rabbit pest are a kind of rabbit infectious diseases as caused by rabbit hemorrhagic disease virus, and morbidity is anxious, infectiousness is strong, the high (Chang Da of the death rate
70% or more).There is no good drug to treat the disease at present, antibiotic and other drugs can only play pre- disease prevention and its
The effect of his complication.Vaccine inoculation is current common preventing control method, wherein traditional rabbit pestilence seedling is Attenuated vaccine,
Production needs to be injected sensitive rabbit with Rabbit pest virus, and preparation process needs carry out under the stringent bio-safety precautionary measures,
Otherwise it is be easy to cause virulent diffusion, additionally needs and uses a large amount of sensitive rabbit, higher cost affects production of vaccine use.Base
Because engineered vaccine is to produce vaccine by cell, it is easier to realize large-scale production compared with Attenuated vaccine, also quality easy to control,
Biological safety is good, while protective rate having the same, will there is broader prospect.But vaccine is mainly the pre- of progress virosis
It is anti-, and can not be treated to rabbit hemorrhagic disease virus rabbit has been infected.It is very heavy that the effective therapeutic agent of rabbit hemorrhagic disease is excavated thus
It wants, and effectively to treat virosis, the most key, the current research report in relation to virus sweep is removed to directly destroying for virus
It is also less.The capsid of viral capsid proteins composition is virus genomic important protective barrier, for the stability of virion
It is most important.But it is not also much realized and develops using viral capsid proteins as the action target of antiviral substance, to virus
The substance that capsid protein is effectively destroyed is expected to successfully develop as ideal virus treatment agent.
Being found from nature to the natural active matter that viral capsid proteins have destruction is that screening obtains virus and controls
Treat the important channel of drug.Plant is the important sources of natural antiviral activity substance, it has been found that many botanical components have
Antiphytoviral, animal virus and human virus, but they are found the direct degradation of viral capsid proteins not yet.
Gossypol is the double naphthalene aldehyde compounds of the root for being largely present in cotton, stem, leaf and a kind of intraseminal yellow polyphenol hydroxyl, in medicine
On be widely used as male contraceptive pill, it has been found that its can antitumor, avian influenza virus etc., be resistant to tomato yellow in agriculturally gossypol
Change leaf curl viral disease, southern black streak dwarf etc..Does gossypol have degradation to the capsid protein of rabbit hemorrhagic disease virus? state
It is inside and outside to yet there are no research report.Present invention research gossypol is to the degrading activity of rabbit hemorrhagic disease virus capsid protein, to obtain one
The healing potion of kind rabbit hemorrhagic disease treats the disease for highly effective and safe, ensures the sound development of rabbit industry.
Three, summary of the invention
1, goal of the invention
A kind of ideal animal virus capsid protein biodegrading process is provided, it can safe disposal rabbit hemorrhagic disease virus capsid egg
It is white, new method is provided for the treatment of the virosis.
2, technical solution
The present invention is a kind of biodegrading process of animal virus capsid protein, it is characterised in that utilizes gossypol degradation rabbit haemorrhagic disease
Viral capsid proteins.
3, beneficial effect
Method of the invention compared with prior art, generates following the utility model has the advantages that the animal virosis of (1) and routine is with pre-
It is compared based on anti-, the present invention removes virus by directly degrading animal virus capsid protein, and prevention and control thinking is new and with strong points；
(2) present invention can improve the nothing of animal virosis using having extensive source and taking the gossypol of Chinese medicine as the mankind conscientiously
Public hazards controlled level.
Four, specific embodiment
The embodiment of the present invention is the method using indoor measurement.
Measuring method is as follows:
1, the prokaryotic expression of viral capsid proteins
Using the method for being based on PAS (PCR-based Accurate Synthesis), design overall length splices primer, synthesis
Capsid Gene of Chinese Isolate of Rabbit Hemorrhagic Disease Virus is connected into carrier pCzn1；The recombinant plasmid pCzn1- capsid protein gene of acquisition is transferred to
TOP10 clone strain and Arctic-ExpressTM express bacterial strain.Use IPTG inducing expression destination protein, Ni column affinity purification
Obtain destination protein.
2, gossypol degradation viral capsid proteins
98% gossypol acetate is dissolved in N ' dinethylformamide and is made into 106Mg/L mother liquor adds to 225mg/L rabbit
In haemorrhagic virus capsid protein, make the final concentration of 100mg/L of gossypol acetate, with without gossypol but contain and 100mg/L cotton
The protein liquid of equal amount N ' dinethylformamide compares in phenol protein liquid, and 20min, egg after processing are placed in 37 DEG C of water-baths
It is white to coagulate amine electrophoresis poststaining through polyacrylamide, it takes pictures.
Implementation result:
The study found that 225mg/L rabbit hemorrhagic disease virus capsid protein through 100mg/L gossypol processing after, at without gossypol
Ratio is managed, protein electrophoresis band obviously dies down, and shows that gossypol acetate has degradation (Fig. 1) to viral capsid proteins.
Detailed description of the invention:
Fig. 1 rabbit hemorrhagic disease virus capsid protein is through gossypol treated SDS-PAGE electrophoresis.
Claims (1)
1. a kind of biodegrading process of animal virus capsid protein, it is characterised in that utilize gossypol degradation rabbit hemorrhagic disease virus capsid egg
White method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811084266.3A CN109125303A (en) | 2018-09-11 | 2018-09-11 | A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811084266.3A CN109125303A (en) | 2018-09-11 | 2018-09-11 | A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125303A true CN109125303A (en) | 2019-01-04 |
Family
ID=64814660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811084266.3A Pending CN109125303A (en) | 2018-09-11 | 2018-09-11 | A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125303A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146527A2 (en) * | 2010-05-17 | 2011-11-24 | Zirus, Inc. | Mammalian genes involved in infection |
| CN105708863A (en) * | 2016-03-21 | 2016-06-29 | 江南大学 | Composition capable of achieving sun protection and preventing infection of mosquito-borne viruses such as Zika virus |
-
2018
- 2018-09-11 CN CN201811084266.3A patent/CN109125303A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146527A2 (en) * | 2010-05-17 | 2011-11-24 | Zirus, Inc. | Mammalian genes involved in infection |
| CN105708863A (en) * | 2016-03-21 | 2016-06-29 | 江南大学 | Composition capable of achieving sun protection and preventing infection of mosquito-borne viruses such as Zika virus |
Non-Patent Citations (1)
| Title |
|---|
| TIONE BURANDA ET AL.: "A High-Throughput Flow Cytometry Screen Identifies Molecules That Inhibit Hantavirus Cell Entry", 《SLAS DISCOVERY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104814985B (en) | Application of a kind of seaweed polysaccharide | |
| CN114377127B (en) | Triple egg yolk antibody preparation and preparation method and application thereof | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| CN112704072B (en) | Application of wood frog antibacterial peptide in preparation of medicine for resisting novel coronavirus SARS-CoV-2 | |
| CN102526568A (en) | Traditional Chinese medicine compound composition | |
| CN102670694B (en) | Traditional Chinese medicine combination for treating porcine pseudorabies and preparation method and application thereof | |
| CN109125303A (en) | A kind of biodegrading process of rabbit hemorrhagic disease virus capsid protein | |
| CN105726742B (en) | A kind of traditional Chinese veterinary medicine against chicken Newcastle disease virus disease and avian influenza and preparation method thereof | |
| CN101209258B (en) | Immunopotentiator and antiviral composition for animal | |
| RU2008130576A (en) | MEDICINAL PREVENTIVE MEANS FOR YOUNG PEOPLE IN AGRICULTURAL ANIMALS AND METHOD FOR PREVENTION AND TREATMENT OF RESPIRATORY DISEASES OF CALVES WITH ITS APPLICATION | |
| CN117752733A (en) | A traditional Chinese medicine fermentation preparation for treating porcine epidemic diarrhea virus infection and its application | |
| CN103784685B (en) | Chinese medicine composition for the treatment of livestock and poultry virus sexually transmitted disease and its preparation method and application | |
| CN109042652A (en) | A kind of biodegrading process of sweet potato chlorotic stunt virus capsid protein | |
| CN110742924B (en) | A kind of Chinese medicine volatile oil composition and application thereof | |
| CN100493605C (en) | Application of human lysozyme in preparation of anti-influenza virus medicine | |
| CN102205118B (en) | Biological product and preparation method thereof | |
| CN101919878A (en) | Application of coryebactrium parvum in preparing medicament for treating novel A H1N1 influenza viruses | |
| CN109105366A (en) | A method of utilizing gossypol degradation Sweet Potato Feathery Mottle Virus capsid protein | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| Bandyopadhyay et al. | Suckling mice of “Belladonna 200” fed mothers evade virulent Nakayama strain Japanese encephalitis virus infection | |
| CN120131654B (en) | Application of tetrandrine in the preparation of drugs for the prevention and treatment of porcine coronavirus | |
| CN101474247A (en) | Application of spatholobus stem extract in preparing medicament for resisting influenza virus and enterovirus | |
| CN112957388B (en) | Application of brassica napus-isatis tinctoria E monomer addition system in inhibiting influenza virus | |
| RU2505305C1 (en) | Method of treating respiratory diseases of calfs | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190104 |